Cartesian Therapeutics

RNAC

시가총액 US$1.9억

FREDERICK, Md., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the granting of inducement awards to four new employees. On October 1, 2026, the Company issued to these employees options to purchase an aggregate of 121,900 shares of the Company's common stock with an exercise price of $7.22, the closing trading price of the Company's common stock on the Nasdaq Global Market on the date of grant. The options were granted pursuant to the Company's Amended and Restated 2018 Employment Inducement Incentive Award Plan and were approved by the Company's board of directors. The options vest as to 25% on October 1, 2027, and then in thirty-six substantially equal monthly installments thereafter such that the options will be fully vested on October 1, 2030. The options have a ten-year term. The options were granted under Rule 5635(c)(4) of the Nasdaq Listing Rules as an inducement material to the employees' entry into employment with the Company.

Descartes–08 demonstrated improvement in mean change from baseline in MG-ADL following initial treatment and retreatment; mean MG-ADL reduction of 6.6 points at Month 12 following retreatment

FREDERICK, Md., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the granting of inducement awards to three new employees.

FREDERICK, Md., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced that its management expects to participate in the following investor conferences in September:

FREDERICK, Md., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the granting of inducement awards to four new employees consisting of options to purchase an aggregate of 115,250 shares of the Company's common stock with effective grant dates of August 3, 2026 and August 6, 2026.

Phase 3 AURORA trial of Descartes-08 in myasthenia gravis (MG) continues to advance; data expected in 1Q27, biologics license application (BLA) filing planned for mid-2027

FREDERICK, Md., July 02, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the granting of inducement awards to eight new employees. On July 1, 2026, the Company issued to these employees options to purchase an aggregate of 238,700 shares of the Company's common stock with an exercise price of $10.18, the closing trading price of the Company's common stock on the Nasdaq Global Market on the date of grant. The options were granted pursuant to the Company's Amended and Restated 2018 Employment Inducement Incentive Award Plan and were approved by the Company's board of directors. The options vest as to 25% on July 1, 2027, and then in thirty-six substantially equal monthly installments thereafter such that the options will be fully vested on July 1, 2030. The options have a ten-year term. The options were granted under Rule 5635(c)(4) of the Nasdaq Listing Rules as an inducement material to the employees' entry into employment with the Company.

CZR, RNAC and NSP have been added to the Zacks Rank #5 (Strong Sell) List on July 1, 2026.

FREDERICK, Md., June 12, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the granting of an inducement award to one new employee.

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) stock is up on Tuesday as the company is announcing a strategic licensing agreement with WestGene Biopharma.